Developmental pharmacokinetics and pharmacodynamics of nizatidine

Journal of Pediatric Gastroenterology and Nutrition

Volumn 38, Issue 4, 2004, Pages 442-451

  Abdel Rahman, Susan M ^a   Johnson, Franklin K ^a   Connor, James D ^a   Staiano, Annamaria ^b   Dupont, Christophe ^b   Tolia, Vasundhara ^b   Winter, Harland ^c   Gauthier Dubois, Ginette ^c   Kearns, Gregory L ^c  

^a Children's Mercy Hospital   (United States)

^b Reliant Pharmaceuticals LLC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Children; Development; Nizatidine; Pharmacodynamics; Pharmacokinetics

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; NIZATIDINE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GASTROESOPHAGEAL REFLUX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLIC CLEARANCE RATE; METABOLISM; MICROCAPSULE; MIDDLE AGED; NEWBORN; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; STOMACH PH; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CAPSULES; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; INFANT; INFANT, NEWBORN; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NIZATIDINE; TREATMENT OUTCOME;

EID: 16544384600     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/00005176-200404000-00015     Document Type: Article

References (26)

1. Vandenplas Y, Hegar B. Diagnosis and treatment of gastrooesophageal reflux disease in infants and children. J Gastroenterol Hepatol 2000;15:593-603.
2. Mezoff AG, Balistreri WF. Peptic ulcer disease in children. Pediatr Rev 1995;16:257-65.
3. 2 receptor antagonists have a therapeutic role in childhood?J Pediatr Gastroenterol Nutr 1994;19:270-6.
4. George DE, Glassman M. Peptic ulcer disease in children. Gastrointest Endosc Clin North Am 1994;4:23-37.
5. Behrens R, Hofbeck M, Singer H, et al. Frequency of stress lesions of the upper gastrointestinal tract in paediatric patients after cardiac surgery: effects of prophylaxis. Br Heart J 1994;72:186-9.
6. 2-receptor antagonists: relationship between intrinsic potency and effective plasma concentrations. Clin Pharmacokinet 1991;20:218-36.
7. Furuta S, Kamada E, Suzuki T, et al. Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole. Xenobiotica 2001;31:1-10.
8. Eland IA, Alvarez CH, Stricker BH, et al. The risk of acute pancreatitis associated with acid-suppressing drugs. Br J Clin Pharmacol 2000;49:473-8.
9. Spiegel JE, Thoden WR, Pappas K, et al. A double-blind, placebo-controlled study of the effectiveness and safety of nizatidine in the prevention of postprandial heartburn. Arch Intern Med 1997;157:1594-9.
10. Thomson AB, Mahachai V, Bailey RJ, et al. Twice daily nizatidine or ranitidine is superior to once daily dosing in elevating 24 hrs intragastric pH in patients with duodenal ulcer disease. J Gastroenterol Hepatol 1996;11:1171-6.
11. Cloud ML, Offen WW. Nizatidine versus placebo in gastrooesophageal reflux disease: a 6-week, multicentre, randomised, double-blind comparison. Br J Clin Pract Suppl 1994;76:11-9.
12. Cloud ML, Offen WW, Robinson M. Nizatidine versus placebo in gastrooesophageal reflux disease: a 12-week, multicentre, randomised, double-blind study. Br J Clin Pract Suppl 1994;76:3-10.
13. Mikawa K, Nishina K, Maekawa N, et al. Effects of oral nizatidine on preoperative gastric fluid pH and volume in children. Br J Anaesth 1994;73:600-4.
14. Simeone D, Caria MC, Miele E, et al. Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. J Pediatr Gastroenterol Nutr 1997;25:51-5.
15. James LP, Marotti T, Stowe CD, et al. Pharmacokinetics and pharmacodynamics of famotidine in infants. J Clin Pharmacol 1998;38:1089-95.
16. Wells TG, Heulitt MJ, Taylor BJ, et al. Pharmacokinetics and pharmacodynamics of ranitidine in neonates treated with extracorporeal membrane oxygenation. J Clin Pharmacol 1998;38:402-7.
17. Lugo RA, Harrison AM, Cash J, et al. Pharmacokinetics and pharmacodynamics of ranitidine in critically ill children. Crit Care Med 2001;29:759-64.
18. Fontana M, Massironi E, Rossi A, et al. Ranitidine pharmacokinetics in newborn infants. Arch Dis Child 1993;68:602-3.
19. Abdel-Rahman SM, Johnson FK, Manowitz N, et al. Single dose pharmacokinetics of nizatidine (Axid®) in children. J Clin Pharmacol 2002;42:1089-96.
20. Abdel-Rahman SM, Johnson FK, Gauthier-Dubois G, et al. The bioequivalence of nizatidine (Axid®) in three extemporaneously and commercially prepared oral liquid formulations compared with capsule. J Clin Pharmacol 2003;43:148-53.
21. Holford NH, Sheiner LB. Pharmacokinetic and pharmacodynamic modeling in vivo. CRC Crit Rev Bioeng 1981;5:273-322.
22. Papadopoulou AZ, Tina LU, Sandler P, et al. Size and function of the kidneys in children are different. In:Developmental Physiology (2nd ed.), Columbus, OH: Ross Laboratories; 1978:97-104.
23. Mathot RAA, Geus WP. Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: characterization of tolerance. Clin Pharmacol Ther 1999;66:140-51.
24. 2-blocker its metabolism and disposition in man. Dispos 1985;14:175-82.
25. Tsai C, Ahdab-Barmada M, Daood MJ, et al. P-glycoprotein expression in the developing human central nervous system: cellular and tissue localization. Pediatr Res 2001;47:436A.
26. Schneck DW, Callaghan JT, Bergstrom RF, et al. Relationship between steady-state plasma nizatidine concentrations and inhibition of basal and stimulated gastric acid secretion. Clin Pharmacol Ther 1990;47:499-503.